A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
暂无分享,去创建一个
S. Kochhar | J. Excler | P. Fast | P. Hayes | J. Cox | J. Gilmour | D. Panicali | Angela Lombardo | E. Sayeed | G. Stevens | P. Narayanan | J. Ackland | J. Mahalingam | S. Solomon | B. Barin | T. Tarragona-Fiol | V. Ramanathan | K. Loughran | C. Verlinde | Makesh Kumar | P. Sathyamoorthy | Sekhar Chakrabarty | Danii Vooijs | Michelle Seth Smith | Pattabiraman Sathyamoorthy
[1] P. Earl,et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. , 2008, The Journal of infectious diseases.
[2] I. M. Belyakov,et al. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. , 2008, Virology.
[3] S. McCormack,et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. , 2008, Vaccine.
[4] Q. Sattentau,et al. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. , 2008, Vaccine.
[5] James M. Wilson,et al. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. , 2008, Human gene therapy.
[6] S. Kochhar,et al. Preparedness for AIDS vaccine trials in India. , 2008, The Indian journal of medical research.
[7] J. Kublin,et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Philip R. Johnson,et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. , 2008, AIDS research and human retroviruses.
[9] John P. Moore,et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.
[10] Todd M. Allen,et al. Crippling HIV one mutation at a time , 2008, The Journal of experimental medicine.
[11] David Heckerman,et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients , 2008, The Journal of experimental medicine.
[12] Dennis R. Burton,et al. Toward an AIDS Vaccine , 2008, Science.
[13] R. Doms,et al. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. , 2008, AIDS research and human retroviruses.
[14] S. McCormack,et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses , 2008, The Journal of experimental medicine.
[15] R. Paranjape,et al. Characterization of B/C recombinants of near full-length HIV type 1 from northeastern India with mosaics identical to ARE195FL but with a different ancestral origin. , 2008, AIDS research and human retroviruses.
[16] Lihan K. Yan,et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. , 2007, Vaccine.
[17] H. McShane,et al. Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials , 2007, PloS one.
[18] P. Seth,et al. Genetic diversity of HIV type 1 subtype C env gene sequences from India. , 2007, AIDS research and human retroviruses.
[19] W. Koff,et al. Scientific and policy challenges to development of an AIDS vaccine , 2007, The Lancet.
[20] J. Mascola,et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. , 2007, Vaccine.
[21] Devan Mehrotra,et al. Detection of HIV Vaccine-Induced Cell-Mediated Immunity in HIV-Seronegative Clinical Trial Participants Using an Optimized and Validated Enzyme-Linked Immunospot Assay , 2007, Journal of acquired immune deficiency syndromes.
[22] G. Pantaleo,et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. , 2007, Vaccine.
[23] J. Margolick,et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. , 2007, The Journal of infectious diseases.
[24] Lihan K. Yan,et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. , 2007, Vaccine.
[25] J. Mascola,et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.
[26] M. Carroll,et al. Recombinant viral vectors: cancer vaccines. , 2006, Advanced drug delivery reviews.
[27] D. Webster,et al. A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge , 2006, Infection and Immunity.
[28] Zoe Moodie,et al. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. , 2006, Journal of immunological methods.
[29] P. Fast. Recent trends in clinical trials of vaccines to prevent HIV/AIDS , 2006, Current opinion in HIV and AIDS.
[30] Lucy Dorrell,et al. Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes , 2006, Journal of Virology.
[31] S. McCormack,et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. , 2006, Vaccine.
[32] A. McMichael,et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. , 2005, Vaccine.
[33] D. Swerdlow,et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. , 2004, Journal of the American College of Cardiology.
[34] W. Heneine,et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. , 2004, AIDS research and human retroviruses.
[35] J. Atwood,et al. Smallpox vaccination and myopericarditis: a clinical review. , 2004, Journal of the American College of Cardiology.
[36] Jorma Hinkula,et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. , 2003, Vaccine.
[37] P. Earl,et al. Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251 , 2003, Journal of Virology.
[38] A. Sahni,et al. Genomic diversity of human immunodeficiency virus type-1 in India , 2002, International journal of STD & AIDS.
[39] G. Sutter,et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. , 2001, The Journal of general virology.
[40] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[41] T. Quinn,et al. Spread of HIV infection in married monogamous women in India. , 1997, JAMA.
[42] R. Brookmeyer,et al. Risk factors and clinical presentation of acute primary HIV infection in India. , 1997, JAMA.
[43] T. Quinn,et al. Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. , 1996, The Indian journal of medical research.
[44] A. McMichael,et al. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. , 2007, The Journal of general virology.
[45] Philip R. Johnson,et al. HIV vaccine design: insights from live attenuated SIV vaccines , 2005, Nature Immunology.
[46] P. Spearman. HIV vaccine development: lessons from the past and promise for the future. , 2003, Current HIV research.
[47] J. Excler,et al. The prime-boost concept applied to HIV preventive vaccines. , 1997, AIDS.